Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxyge... (enrolled patients in ablinded fashion. T...)

Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers

Date:4/29/2008

enrolled patients in a blinded fashion. They used objective criteria to classify the MIs in the study as "possible," "probable," "indeterminate," and "absent." More than half the patients in both study groups had some evidence of myocardial infarction. [See table.]

IDMC Cardiac Subcommittee MI Analysis

PolyHeme(R) Control

(n=349) (n=365)

Probable MI 42 (12%) 30 (8%)

Possible MI 145 (42%) 159 (44%)

Total 187 (54%) 189 (52%)

Indeterminate 79 (23%) 112 (31%)

Absent MI 83 (24%) 64 (18%)

"This is useful information, which confirms the difficulty of diagnosing cardiac ischemia in trauma patients," said Dr. Gould.

Dr. Gould concluded his presentation by summarizing the development of PolyHeme(R). "We believe our studies demonstrate that PolyHeme(R) offers a survival benefit in cases of life-threatening red blood cell hemoglobin levels and has an acceptable safety profile and favorable benefit-to-risk ratio when red blood cells are not available."

About Northfield Laboratories and PolyHeme(R)

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. Northfield's product, PolyHeme(R), is under clinical investigation as oxygen-carrying red blood cell substitute. It is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit http://www.northfieldlabs.com.

Forward Lo
'/>"/>

SOURCE Northfield Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
2. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
3. Romark Laboratories Raises $18 Million in Institutional Financing
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
8. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
9. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
11. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors

Post Your Comments:

(Date:11/25/2009)....25/PRNewswire/--Reportlinker.comannouncesthatanew..., UnitedStatesDentalDevicesMarketAnalysisandFore...158733/United-States-Dental-Devices-Market-Analysi...ntalDevicesMarketAnalysisandForecaststo2015 ,, ...-depthinformationanddatarelatingtotheUSdentaldevic...

(Date:11/25/2009)...alif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Na...oint-of-carebloodanalysissystems,announcedtodaytha...llpresentatthe21stAnnualPiperJaffrayHealthCareConf...nferencewillbeheldattheNewYorkPalaceHotelinNewYork...ufacturesandmarketsportablebloodanalysissystemsfor...

(Date:11/25/2009)...s.,Nov.25/PRNewswire/--AccordingtoMillenniumResear...marketintelligence,thenearly$3billionUSmarketfortr...rthenextfiveyearsdespitetherecenteconomicslowdown....hatthismarketwillremainhighlydynamicoverthenextfiv...sinpreviouslyunderservedsegmentsofthetraumafixatio...

[0] Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 [0] Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference [0] US Trauma Fixation Device Market Not Seeing Signs of Slowdown

..., a leading,provider of systems for safe fluid han...es the addition of two new international product,d...rma Trading Corporation,in Colombia and Pentafarma...xa to extend its global reach and expand product p...bal markets offer significant potential for growth...

...invigorated Effort to Design ...e AIDS Vaccine Advocacy,Coalition (AVAC) released ...tchell Warren about the announcement that vaccinat...est-of-concept trial of the MRK-Ad5 AIDS,vaccine c...ies: "Today,s announcement about the STEP Study i...

Other Medicine Technology:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2 AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result 2 AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result 3

Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result

(Date:11/25/2009)...tically significant survival benefit from adjuvant...(ER)-positive tumors had high levels of phosphoryl..., according to a brief communication published onl...ncer Institute . , Approximately 50% of breast c...studies have shown that ER-alpha S118-P is require...

(Date:11/25/2009)...rthritis, could help newly diagnosed diabetics, st...Day News) -- A drug commonly used to treat non-Hod...shows some promise in helping patients newly diagn...b (Rituxan), helped patients keep producing some o...estroyed some of their pancreatic beta cells, whic...

(Date:11/25/2009)...trouble with the H1N1 vaccine, , , WEDN...1 swine flu pandemic may be driving a recent spike... U.S. health official said Wednesday. , "We are...ions around the country," Dr. Anne Schuchat, direc...spiratory Diseases at the U.S. Centers for Disease...

(Date:11/25/2009)...d into the body on a carefully engineered, fingern...minate tumors in mammals, scientists report this w... . , The new approach, pioneered by bioengineers...stic disks impregnated with tumor-specific antigen...mmalian immune system to attack tumors. The new pa...

(Date:11/25/2009)...ed parts of speech colored perception of sounds ,... People can "hear" not only with their ears, but a...act, sensations on the skin designed to mimic cert...r sounds better, the Canadian scientists found. ,...ld use tactile information in this way," said Brya...

Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2 Health News:Type 1 Diabetes May Have a New Foe 3 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4 Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2 Health News:Your Skin Can Help Your Ears Listen 2 Health News:Your Skin Can Help Your Ears Listen 3

[1] News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response [1] Type 1 Diabetes May Have a New Foe [0] Swine Flu Tied to Rise in Pneumonias Among Young [1] Implant-based cancer vaccine is first to eliminate tumors in mice [0] Your Skin Can Help Your Ears Listen

... finds therapy has capacity to repair nerve fiber ...ews) -- The drug Tysabri (natalizumab) appears to ... sheath in people with multiple sclerosis (MS), a ... MS patients are caused by damage to the myelin sh...

...ndong, China, April 29 /PRNewswire-Asia-FirstCall/...ard: SGTI) ("Shengtai" or "the Company"),a leading...rmaceutical grade,glucose products in China, today...ell as conducted,high-level discussions with key e...

...l 29 , - Bausch & Lomb Launches New Bottl...aign , Bausch & Lomb unveils a ground-brea...se solutions in its continued effort to improve th...tiPlus(R) for,improved comfort and MPS for sensiti...

...rter Reported Diluted Earnings per Share were $0.8...d Earnings per Share, , Excluding Certain Signi...de Net Revenue Decreased 6% for the 2009 First Qua...change, was Driven by Increases of 23% for Enbrel ...

...GOED UNTIL WEDNESDAY - 29. APRIL 2009 AT 13.00 CET...llowing doctors to detect hidden diseases and make...ty experts at the International Atomic Energy Agen...on with other international organizations, is deve...

...Bill to Advance Education and Informed Consent Rec...cine , , SAN BRUNO, Calif., April 29 Cord Blood...ion and preservation of newborn stem cells from um...reness Act of 2009." If passed, this ground-break...

Tysabri May Treat Myelin Sheath Damage From MS Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference A Clear Solution for Healthy Eyes Wyeth Reports Earnings Results for the 2009 First Quarter IAEA calls for enhanced radiation protection of patients Cord Blood Registry Supports Introduction of the Cord Blood Education and Awareness Act of 2009

PhotoLight Pulsed Light System

Apogee Elite Two-in-One Laser System

THORACOPORT™ Soft (Single Use Trocars With Conductive Sleeves)

VersaStep™ Reposable (Reusable Components - Standard Length)

Medicine Products:

PhotoLight Pulsed Light System Apogee Elite Two-in-One Laser System THORACOPORT™ Soft (Single Use Trocars With Conductive Sleeves)VersaStep™ Reposable (Reusable Components - Standard Length)

Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxyge...(enrolled patients in ablinded fashion. T...),Health